U.S. Patent and Trademark Office; U.S. DEPARTMEN' Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid Office.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10575073	
Filing Date		2006-04-07	
First Named Inventor Velet		ony et al.	
Art Unit			_
Examiner Name			Τ
Attorney Docket Numb	er	KANIA-08	

				U.S	PATENTS			Remove		
Examiner Initial*	er Cite No Patent Number Kind Code1 Issue Date Name of Patentee o of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear						
	1	6391864	B1	2002-05-21	Stone					
	2	6495148	B1	2002-12-17	Abbiati					
If you wisl	h to a	dd additional U.S. Pate	ent citatio	n information p	lease click the	Add button.	_	Add		
			U.S.P	ATENT APPL	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Kind Code ¹ Publication Name of Patentee or Applica of cited Document			Releva		Lines where ges or Relev	
	1	20030050277	A1	2003-03-13	Kajimoto et a	L				
If you wis	h to a	dd additional U.S. Pub	lished Ap	olication citation	n information	please click the Ad	d buttor	Add		
			•	FOREIGN PA	TENT DOCU	MENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	т.
	1	2004137183	JP	A	2004-05-13	Kotobuki et al.				
	2	2003212781	JP	A	2003-07-30	Maruzen et al.				

2004-08-26 Bisig et al.

Α1

	4	WO2003/099992	wo	A2	2003-12-04	LI et al.		
	5	WO1997/33592	wo	A1	1997-09-18	Pilarski et al.		
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	Add	
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*								T5
	1 PCT, International Search Report, PCT/CZ2004/00064, dated 08/10/04, pp3							
	STANCIKOVA M. ET AL. "The effects of hystaxonan on bone responsion and bone mineral density in a rat model of estrogen efficiently-induced obsequent BRTERNATIONAL JOURNAL OF TISSUE REACTIONS 2004 SWITZERLAND, vol. 2, pm. 142, 2004, page 9-19							
	Nakamura et al: "High, but not low, molecular liver injury by reducing proinflammatory cytokines in mice" JOURNAL OF GASTROENTEROLOGY, vol. 39, no. 4, April 2004, Pg. 346-354							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

1 See Nnt Cotes of USPTO Petent Documents at invent USPTO COV or MPPS 901.04. 2 Enter office that issued the document, by the two-left covering Sharing S13.0 3 1 Feet appresses peter for counters, the noticeation of the year of the region of the Empirer among precise the sent among the efficiency and precise the sent among the efficiency and the sent of the peter document of the peter document by the appropriate symbols as andicated on the document under WIPO Standard S11.6 if possible, 2 Applicant is to place a check mark here if Empirels hargings the resident on state-doct.

Date Considered

Examiner Signature

3

WO2004/071543

wo

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GPR 199)

Application Number		10575073
Filing Date		2006-04-07
First Named Inventor	Velet	ony et al.
Art Unit		
Examiner Name		
Attorney Docket Numb	er	KANIA-08

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication of forms foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sideologue statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Beverly A. Lyman/	Date (YYYY-MM-DD)	2006-07-05
Name/Print	Beverly A. Lyman, Ph. D.	Registration Number	41961

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examines your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission of the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet for disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via fifed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.